<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Current Issue</title>
    <link>http://jama.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 21 May 2013 20:43:18 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@jama.jamanetwork.com</managingEditor>
    <webMaster>webmaster@jama.jamanetwork.com</webMaster>
    <item>
      <title>This Week in JAMA</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690704</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;May 22/29, 2013&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2065</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2065</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5769</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690704</guid>
    </item>
    <item>
      <title>Advances in Regulatory Science at the Food and Drug Administration Advances in Regulatory Science at the FDA </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690705</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Psaty BM, Goodman SN, Breckenridge A. </author>
      <description>&lt;span class="paragraphSection"&gt;Since the Kefauver-Harris amendments of 1962, the US Food and Drug Administration (FDA) has required evidence of efficacy to approve a drug for marketing in the United States. For many years, information about benefits and risks was assembled at the time of approval, and if the benefits appeared to exceed the risks known at the time, the drug was deemed safe for approval. In practice, a drug that demonstrated efficacy according to the prespecified outcomes in the phase 3 trials was approved for marketing unless there was convincing evidence of a serious risk.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2103</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2104</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4503</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690705</guid>
    </item>
    <item>
      <title>Identification of Physician Impairment Identification of Physician Impairment </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1682565</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Pham J, Pronovost PJ, Skipper GE. </author>
      <description>&lt;span class="paragraphSection"&gt;When a critical event occurs in most high-risk industries (such as airlines, nuclear power, or railways), a detailed investigation examines a variety of system and individual factors (such as fatigue and substance abuse) that caused or contributed to the event. Directly involved individuals are commonly tested for alcohol and other drugs. Airplane pilots and truck drivers are tested following crashes and near misses. Some law enforcement officers are tested following fatal shooting incidents.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2101</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2102</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4635</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1682565</guid>
    </item>
    <item>
      <title>Medication Nonadherence A Diagnosable and Treatable Medical Condition  Medication Nonadherence </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690707</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Marcum ZA, Sevick M, Handler SM. </author>
      <description>&lt;span class="paragraphSection"&gt;Medication nonadherence is widely recognized as a common and costly problem. Approximately 30% to 50% of US adults are not adherent to long-term medications leading to an estimated $100 billion in preventable costs annually. The barriers to medication adherence are similar to other complex health behaviors, such as weight loss, which have multiple contributing factors. Despite the widespread prevalence and cost of medication nonadherence, it is undetected and undertreated in a significant proportion of adults across care settings. According to the World Health Organization, “increasing the effectiveness of adherence interventions may have far greater impact on the health of the population than any improvement in specific medical treatments.” How can adherence be improved? We propose that the first step is to view medication nonadherence as a diagnosable and treatable medical condition.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2105</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2106</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4638</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690707</guid>
    </item>
    <item>
      <title>Value of Unique Device Identification in the Digital Health Infrastructure Unique Device Identification </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690708</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Wilson NA, Drozda J. </author>
      <description>&lt;span class="paragraphSection"&gt;In recent years, high-profile cases of medical device failure resulting in patient harm—such as implantable cardioverter-defibrillator leads and metal-on-metal hip implants—have received substantial attention both in the medical literature and popular press. These examples illustrate the need for a more effective system of monitoring device performance and protecting patient safety.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2107</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2108</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5514</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690708</guid>
    </item>
    <item>
      <title>The Proud Paratrooper</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690702</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Baggett TP. </author>
      <description>&lt;span class="paragraphSection"&gt;Darkness surrendered to the Saturday dawn, unveiling a canvas of clear blue sky illuminated by the heatless light of a harshly cold winter morning. It was January in Boston. I backed my car into an empty parking space on Paul Sullivan Way, in the shadows of the Pine Street Inn homeless shelter. The digital clock on the dashboard read 6:58 AM. Across the street, a blanketed man hunkered down in an abandoned doorway. Skirting patches of ice on a broken sidewalk, I rounded the corner onto Harrison Avenue and entered the shelter. The smell of alcohol and rotten feet hit my nose. Inside the shelter's medical clinic, a seasoned nurse was already tending to a crowd of patients.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2109</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2110</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.3044</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690702</guid>
    </item>
    <item>
      <title>Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia Results of the REMIT Trial  Escitalopram and Stress-Induced Myocardial Ischemia </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690699</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Jiang W, Velazquez EJ, Kuchibhatla M, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress–induced myocardial ischemia (MSIMI) have not been well studied.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To examine the effects of 6 weeks of escitalopram treatment vs placebo on MSIMI and other psychological stress–related biophysiological and emotional parameters.&lt;div class="boxTitle"&gt;Design, Setting, and Participants&lt;/div&gt;The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI. Enrollment occurred from July 24, 2007, through August 24, 2011, at a tertiary medical center.&lt;div class="boxTitle"&gt;Interventions&lt;/div&gt;Eligible participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20 mg/d in 3 weeks) or placebo over 6 weeks.&lt;div class="boxTitle"&gt;Main Outcomes and Measures&lt;/div&gt;Occurrence of MSIMI, defined as development or worsening of regional wall motion abnormality; left ventricular ejection fraction reduction of 8% or more; and/or horizontal or down-sloping ST-segment depression of 1 mm or more in 2 or more leads, lasting for 3 or more consecutive beats, during 1 or more of 3 mental stressor tasks.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Of 127 participants randomized to receive escitalopram (n = 64) or placebo (n = 63), 112 (88.2%) completed end point assessments (n = 56 in each group). At the end of 6 weeks, more patients taking escitalopram (34.2% [95% CI, 25.4%-43.0%]) had absence of MSIMI during the 3 mental stressor tasks compared with patients taking placebo (17.5% [95% CI, 10.4%-24.5%]), based on the unadjusted multiple imputation model for intention-to-treat analysis. A significant difference favoring escitalopram was observed (odds ratio, 2.62 [95% CI, 1.06-6.44]). Rates of exercise-induced ischemia were slightly lower at 6 weeks in the escitalopram group (45.8% [95% CI, 36.6%-55.0%]) than in patients receiving placebo (52.5% [95% CI, 43.3%-61.8%]), but this difference was not statistically significant (adjusted odds ratio; 1.24 [95% CI, 0.60-2.58]; P = .56).&lt;div class="boxTitle"&gt;Conclusions and Relevance&lt;/div&gt;Among patients with stable coronary heart disease and baseline MSIMI, 6 weeks of escitalopram, compared with placebo, resulted in a lower rate of MSIMI. There was no statistically significant difference in exercise-induced ischemia. Replication of these results in multicenter settings and investigations of other medications for reducing MSIMI are needed.&lt;div class="boxTitle"&gt;Trial Registration&lt;/div&gt;clinicaltrials.gov Identifier: NCT00574847 .&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2139</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2149</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5566</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690699</guid>
    </item>
    <item>
      <title>Early Parenteral Nutrition in Critically Ill Patients With Short-term Relative Contraindications to Early Enteral Nutrition A Randomized Controlled Trial  Early Parenteral Nutrition in Critically Ill Patients </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1689534</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Doig GS, Simpson F, Sweetman EA, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Systematic reviews suggest adult patients in intensive care units (ICUs) with relative contraindications to early enteral nutrition (EN) may benefit from parenteral nutrition (PN) provided within 24 hours of ICU admission.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To determine whether providing early PN to critically ill adults with relative contraindications to early EN alters outcomes.&lt;div class="boxTitle"&gt;Design, Setting, and Participants&lt;/div&gt;Multicenter, randomized, single-blind clinical trial conducted between October 2006 and June 2011 in ICUs of 31 community and tertiary hospitals in Australia and New Zealand. Participants were critically ill adults with relative contraindications to early EN who were expected to remain in the ICU longer than 2 days.&lt;div class="boxTitle"&gt;Interventions&lt;/div&gt;Random allocation to pragmatic standard care or early PN.&lt;div class="boxTitle"&gt;Main Outcomes and Measures&lt;/div&gt;Day-60 mortality; quality of life, infections, and body composition.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;A total of 1372 patients were randomized (686 to standard care, 686 to early PN). Of 682 patients receiving standard care, 199 patients (29.2%) initially commenced EN, 186 patients (27.3%) initially commenced PN, and 278 patients (40.8%) remained unfed. Time to EN or PN in patients receiving standard care was 2.8 days (95% CI, 2.3 to 3.4). Patients receiving early PN commenced PN a mean of 44 minutes after enrollment (95% CI, 36 to 55). Day-60 mortality did not differ significantly (22.8% for standard care vs 21.5% for early PN; risk difference, −1.26%; 95% CI, −6.6 to 4.1; P = .60). Early PN patients rated day-60 quality of life (RAND-36 General Health Status) statistically, but not clinically meaningfully, higher (45.5 for standard care vs 49.8 for early PN; mean difference, 4.3; 95% CI, 0.95 to 7.58; P = .01). Early PN patients required fewer days of invasive ventilation (7.73 vs 7.26 days per 10 patient × ICU days, risk difference, −0.47; 95% CI, −0.82 to −0.11; P = .01) and, based on Subjective Global Assessment, experienced less muscle wasting (0.43 vs 0.27 score increase per week; mean difference, −0.16; 95% CI, −0.28 to −0.038; P = .01) and fat loss (0.44 vs 0.31 score increase per week; mean difference, −0.13; 95% CI, −0.25 to −0.01; P = .04).&lt;div class="boxTitle"&gt;Conclusions and Relevance&lt;/div&gt;The provision of early PN to critically ill adults with relative contraindications to early EN, compared with standard care, did not result in a difference in day-60 mortality. The early PN strategy resulted in significantly fewer days of invasive ventilation but not significantly shorter ICU or hospital stays.&lt;div class="boxTitle"&gt;Trial Registration&lt;/div&gt;anzctr.org.au Identifier: ACTRN012605000704695&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2130</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2138</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5124</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1689534</guid>
    </item>
    <item>
      <title>Effect of Early vs Late Tracheostomy Placement on Survival in Patients Receiving Mechanical Ventilation The TracMan Randomized Trial  Early vs Late Tracheostomy Placement </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690674</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Young D, Harrison DA, Cuthbertson BH, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Tracheostomy is a widely used intervention in adult critical care units. There is little evidence to guide clinicians regarding the optimal timing for this procedure.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To test whether early vs late tracheostomy would be associated with lower mortality in adult patients requiring mechanical ventilation in critical care units.&lt;div class="boxTitle"&gt;Design and Setting&lt;/div&gt;An open multicentered randomized clinical trial conducted between 2004 and 2011 involving 70 adult general and 2 cardiothoracic critical care units in 13 university and 59 nonuniversity hospitals in the United Kingdom.&lt;div class="boxTitle"&gt;Participants&lt;/div&gt;Of 1032 eligible patients, 909 adult patients breathing with the aid of mechanical ventilation for less than 4 days and identified by the treating physician as likely to require at least 7 more days of mechanical ventilation.&lt;div class="boxTitle"&gt;Interventions&lt;/div&gt;Patients were randomized 1:1 to early tracheostomy (within 4 days) or late tracheostomy (after 10 days if still indicated).&lt;div class="boxTitle"&gt;Main Outcomes and Measures&lt;/div&gt;The primary outcome measure was 30-day mortality and the analysis was by intention to treat.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Of the 455 patients assigned to early tracheostomy, 91.9% (95% CI, 89.0%-94.1%) received a tracheostomy and of 454 assigned to late tracheostomy, 44.9% (95% CI, 40.4%-49.5%) received a tracheostomy. All-cause mortality 30 days after randomization was 30.8% (95% CI, 26.7%-35.2%) in the early and 31.5% (95% CI, 27.3%-35.9%) in the late group (absolute risk reduction for early vs late, 0.7%; 95% CI, −5.4% to 6.7%). Two-year mortality was 51.0% (95% CI, 46.4%-55.6%) in the early and 53.7% (95% CI, 49.1%-58.3%) in the late group (P = .74). Median critical care unit length of stay in survivors was 13.0 days in the early and 13.1 days in the late group (P = .74). Tracheostomy-related complications were reported for 6.3% (95% CI, 4.6%-8.5%) of patients (5.5% in the early group, 7.8% in the late group).&lt;div class="boxTitle"&gt;Conclusions and Relevance&lt;/div&gt;For patients breathing with the aid of mechanical ventilation treated in adult critical care units in the United Kingdom, tracheostomy within 4 days of critical care admission was not associated with an improvement in 30-day mortality or other important secondary outcomes. The ability of clinicians to predict which patients required extended ventilatory support was limited.&lt;div class="boxTitle"&gt;Trial Registration&lt;/div&gt;isrctn.org Identifier: ISRCTN28588190&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2121</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2129</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5154</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690674</guid>
    </item>
    <item>
      <title>Effects of Targeting Higher vs Lower Arterial Oxygen Saturations on Death or Disability in Extremely Preterm Infants A Randomized Clinical Trial  Arterial Oxygen Saturation Levels in Preterm Infants </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1684963</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Schmidt B, Whyte RK, Asztalos EV, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;The goal of oxygen therapy is to deliver sufficient oxygen to the tissues while minimizing oxygen toxicity and oxidative stress. It remains uncertain what values of arterial oxygen saturations achieve this balance in preterm infants.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To compare the effects of targeting lower or higher arterial oxygen saturations on the rate of death or disability in extremely preterm infants.&lt;div class="boxTitle"&gt;Design, Setting, and Participants&lt;/div&gt;Randomized, double-blind trial in 25 hospitals in Canada, the United States, Argentina, Finland, Germany, and Israel in which 1201 infants with gestational ages of 23 weeks 0 days through 27 weeks 6 days were enrolled within 24 hours after birth between December 2006 and August 2010. Follow-up assessments began in October 2008 and ended in August 2012.&lt;div class="boxTitle"&gt;Interventions&lt;/div&gt;Study participants were monitored until postmenstrual ages of 36 to 40 weeks with pulse oximeters that displayed saturations of either 3% above or below the true values. Caregivers adjusted the concentration of oxygen to achieve saturations between 88% and 92%, which produced 2 treatment groups with true target saturations of 85% to 89% (n = 602) or 91% to 95% (n = 599). Alarms were triggered when displayed saturations decreased to 86% or increased to 94%.&lt;div class="boxTitle"&gt;Main Outcomes and Measures&lt;/div&gt;The primary outcome was a composite of death, gross motor disability, cognitive or language delay, severe hearing loss, or bilateral blindness at a corrected age of 18 months. Secondary outcomes included retinopathy of prematurity and brain injury.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Of the 578 infants with adequate data for the primary outcome who were assigned to the lower target range, 298 (51.6%) died or survived with disability compared with 283 of the 569 infants (49.7%) assigned to the higher target range (odds ratio adjusted for center, 1.08; 95% CI, 0.85 to 1.37; P = .52). The rates of death were 16.6% for those in the 85% to 89% group and 15.3% for those in the 91% to 95% group (adjusted odds ratio, 1.11; 95% CI, 0.80 to 1.54; P = .54). Targeting lower saturations reduced the postmenstrual age at last use of oxygen therapy (adjusted mean difference, −0.8 weeks; 95% CI, −1.5 to −0.1; P = .03) but did not alter any other outcomes.&lt;div class="boxTitle"&gt;Conclusion and Relevance&lt;/div&gt;In extremely preterm infants, targeting oxygen saturations of 85% to 89% compared with 91% to 95% had no significant effect on the rate of death or disability at 18 months. These results may help determine the optimal target oxygen saturation.&lt;div class="boxTitle"&gt;Trial Registrations&lt;/div&gt;ISRCTN Identifier: 62491227; ClinicalTrials.gov Identifier: NCT00637169JAMA. 2013;309(20):2111-2120&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2111</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2120</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5555</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1684963</guid>
    </item>
    <item>
      <title>Management of Active Crohn Disease Management of Active Crohn Disease </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690713</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Cheifetz AS. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Treatment of Crohn disease is rapidly evolving, with the induction of novel biologic therapies and newer, often more intensive treatment approaches. Knowing how to treat individual patients in this quickly changing milieu can be a challenge.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To review the diagnosis and management of moderate to severe Crohn disease, with a focus on newer treatments and goals of care.&lt;div class="boxTitle"&gt;Evidence Review&lt;/div&gt;MEDLINE was searched from 2000 to 2011. Additional citations were procured from references of select research and review articles. Evidence was graded using the American Heart Association level-of-evidence guidelines.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Although mesalamines are still often used to treat Crohn disease, the evidence for their efficacy is lacking. Corticosteroids can be effectively used to induce remission in moderate to severe Crohn disease, but they do not maintain remission. The mainstays of treatment are immunomodulators and biologics, particularly anti–tumor necrosis factor.&lt;div class="boxTitle"&gt;Conclusion and Relevance&lt;/div&gt;Immunomodulators and biologics are now the preferred treatment options for Crohn disease.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2150</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2158</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4466</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690713</guid>
    </item>
    <item>
      <title>Sudden Purpuriform Rash in an Infant Sudden Purpuriform Rash in an Infant </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690675</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Scheer H, Weibel L. </author>
      <description>&lt;span class="paragraphSection"&gt;A 10-month-old boy presents with erythematous swelling of bothears and right eyelid and erythematous perioral macules following a respiratory tract infection 12 days before presentation (Figure, A). Within 4 days the lesions increased in size, becoming large erythematous plaques on the face (Figure, B). Targetoid, purpuric lesions developed on the limbs (Figure, C), along with hand edema. There were no trunk lesions and no involvement of the mucous membranes. The child is otherwise in good general health. On examination he is afebrile, has normal vital signs, and there is no lymphadenopathy or organomegaly. Findings from urinalysis, complete blood cell count, coagulation studies, and liver and kidney function studies are unremarkable.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2159</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2160</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4794</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690675</guid>
    </item>
    <item>
      <title>Early Nutrition in Critically Ill Patients Feed Carefully and in Moderation  Early Nutrition in Critically Ill Patients </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1689533</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Ochoa Gautier JB, Machado FR. </author>
      <description>&lt;span class="paragraphSection"&gt;Clinicians in intensive care units (ICUs) have to decide whether supplemental parenteral nutrition should be ordered for a critically ill patient who cannot be fed and is kept “nil per os (NPO),” for instance, because of gastrointestinal tract dysfunction. Without early supplemental parenteral nutrition, the patient is temporarily starved, an approach based on the assumption that physiologic compensatory processes are protective and thus there will be no untoward clinical consequences. In contrast, clinicians who order early supplemental parenteral nutrition presumably consider the accumulating caloric deficit to be deleterious for critically ill patients. Although determining the best approach might seem straightforward, a clear answer remains evasive.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2165</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2166</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4867</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1689533</guid>
    </item>
    <item>
      <title>Oxygenation Targets and Outcomes in Premature Infants Oxygenation Targets and Outcomes in Premature Infants </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1684964</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Bancalari E, Claure N. </author>
      <description>&lt;span class="paragraphSection"&gt;Many premature infants experience respiratory failure and receive supplemental oxygen for prolonged periods. While this therapy is crucial for their survival, it can be associated with complications such as retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and central nervous system damage. In recent years, to minimize these complications clinicians have targeted progressively lower arterial oxygen saturation (SpO&lt;sub&gt;2&lt;/sub&gt;) levels in these infants. This occurred despite little evidence for the efficacy and safety of this approach. Several randomized controlled trials have been conducted to test if targeting oxygen saturations in the lower (85%-89%) vs the upper (91%-95%) part of the recommended range confer advantages in regard to neurodevelopmental outcome and severe ROP in extremely premature infants.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2161</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2162</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5831</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1684964</guid>
    </item>
    <item>
      <title>When Should a Mechanically Ventilated Patient Undergo Tracheostomy? Timing for Tracheostomy </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690679</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Angus DC. </author>
      <description>&lt;span class="paragraphSection"&gt;Each year, approximately 800 000 US residents undergo mechanical ventilation for acute respiratory insufficiency, often for a period of days or weeks. Although mechanical ventilation can be lifesaving, it is unnatural and invasive, can be extremely uncomfortable, and requires expensive intensive care support. Endotracheal intubation is the most efficient and convenient method by which to initiate mechanical ventilation. However, intubation is often not well tolerated by an awake patient; is prone to potentially disastrous dislodgement; and interferes with oral care, feeding, and communication.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2163</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2164</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.6014</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690679</guid>
    </item>
    <item>
      <title>Care for Transgender Persons</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690690</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Lawrence AA, Zucker KJ. </author>
      <description>&lt;span class="paragraphSection"&gt;To the Editor: The article by Dr Spack concerning the management of persons with gender identity disorders misstated the prerequisites for cross-sex hormone therapy and omitted any explanation of transsexual subtypes. Spack stated that adults should be living full-time as the opposite gender to be eligible for cross-sex hormone therapy.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2093</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2094</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4665</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690690</guid>
    </item>
    <item>
      <title>Care for Transgender Persons</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690689</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Danoff A, Daskalakis D, Aberg JA. </author>
      <description>&lt;span class="paragraphSection"&gt;To the Editor: In a Clinical Crossroads article, Dr Spack reviewed key elements of psychological, hormonal, and surgical management of transgender and transsexual individuals. We suggest that testing for human immunodeficiency virus (HIV) also should be included as an integral component of transgender care.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2092</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2093</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4662</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690689</guid>
    </item>
    <item>
      <title>Care for Transgender Persons—Reply</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690691</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Spack NP. </author>
      <description>&lt;span class="paragraphSection"&gt;In Reply: Dr Danoff and colleagues raise the issue of HIV testing in transgender care. Considering the data from the meta-analysis of 29 studies, it would be worthwhile for guidelines and review articles to mention the higher prevalence of HIV reported among transgender persons. Optimally, all transgender individuals would have a primary care physician to take a careful sexual history, discuss HIV risks, and offer screening. In the absence of a primary care physician, another physician involved in the patient's care should assume this role.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2093</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2094</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4668</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690691</guid>
    </item>
    <item>
      <title>Duty Hour Reforms in Europe and the United States</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690692</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Holsgrove DT. </author>
      <description>&lt;span class="paragraphSection"&gt;To the Editor: The Viewpoint by Dr Axelrod and colleagues on the implications of the introduction of the European Working Time Directive on medical care and education highlighted important factors to be considered when reducing the working hours of physicians in training. However, it did not fully appreciate the protracted implementation of the legislation.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2094</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2095</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4081</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690692</guid>
    </item>
    <item>
      <title>Duty Hour Reforms in Europe and the United States—Reply</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690693</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Axelrod L, Shah DJ, Jena AB. </author>
      <description>&lt;span class="paragraphSection"&gt;In Reply: Duty hour reforms in the United States and Europe have sparked vigorous debate about optimal trade-offs that must be made among the well-being of physicians in training, the continuity of care provided to patients, and the necessary experience required to prepare physicians for independent practice after completion of postgraduate medical training. Our description of the European Working Time Directive was intended to fuel further discussion and research into whether the pendulum has swung too far in Europe, where duty hour restrictions are greater than in the United States.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2094</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2095</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4096</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690693</guid>
    </item>
    <item>
      <title>End Points in Trials of Treatments for Skin Infections</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690687</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Spellberg B. </author>
      <description>&lt;span class="paragraphSection"&gt;To the Editor: In accord with US Food and Drug Administration guidance for skin infection clinical trials, Dr Prokocimer and colleagues reported an early “cessation of lesion spread” analysis as their primary end point in a trial of tedizolid phosphate vs linezolid for acute bacterial skin and skin structure infections (ABSSSIs). Thus, patients with skin infections were deemed treatment successes if the skin infection did not worsen after receiving antibiotic therapy for 3 days.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2091</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2092</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4541</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690687</guid>
    </item>
    <item>
      <title>End Points in Trials of Treatments for Skin Infections—Reply</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690688</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Prokocimer P, Das A. </author>
      <description>&lt;span class="paragraphSection"&gt;In Reply: Dr Spellberg raises the question of whether a cessation of lesion spread in ABSSSIs can be considered a cure of the disease. This issue was discussed by the Foundation for the National Institutes of Health working group on end points in ABSSSIs. The group's recommended end point is a 20% or greater decrease in lesion size at the 48- to 72-hour assessment rather than cessation of spread at this time point.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2091</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2092</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4550</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690688</guid>
    </item>
    <item>
      <title>Residual Gastric Volume and Risk of Ventilator-Associated Pneumonia</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690685</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Elke G, Heyland D. </author>
      <description>&lt;span class="paragraphSection"&gt;To the Editor: Dr Reignier and colleagues provided evidence that not measuring residual gastric volume and adjusting enteral nutrition except in the case of vomiting or regurgitation (intervention group) did not negatively affect clinical outcomes compared with checking residual gastric volume 4 times per day and adjusting enteral feeding rates if the volume exceeded 250 mL (control group). The conclusion given by the authors that monitoring residual gastric volume should be discontinued in all patients receiving mechanical ventilation and early enteral nutrition is, in our opinion, an overstatement, because we believe that the external validity of the trial is limited.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2090</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2091</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4090</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690685</guid>
    </item>
    <item>
      <title>Residual Gastric Volume and Risk of Ventilator-Associated Pneumonia—Reply</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690686</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Reignier J, Lascarrou J. </author>
      <description>&lt;span class="paragraphSection"&gt;In Reply: Despite the data obtained in our trial, Drs Elke and Heyland state that by continuously monitoring residual gastric volume, clinicians can detect more readily patients with delayed gastric emptying and intervene with strategies that minimize the risk of enteral nutrition. However, guidelines state that “residual gastric volumes in the range of 200-500 mL should raise concern and lead to the implementation of measures to reduce risk of aspiration” and acknowledge that “residual gastric volume does not correlate well to incidence of pneumonia, measures of gastric emptying, or incidence of regurgitation and aspiration.”&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2090</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2091</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4093</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690686</guid>
    </item>
    <item>
      <title>CDC: Use Antivirals Early, Aggressively for H7N9 Flu</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690697</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;The US Centers for Disease Control and Prevention (CDC) is advising clinicians to begin antiviral treatment as soon as possible for individuals with suspected or confirmed H7N9 influenza infection, according to a guidance document issued by the agency in April (http://tinyurl.com/d4gzab7).&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2086</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2086</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.6086</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690697</guid>
    </item>
    <item>
      <title>Growing Use of Genomic Data Reveals Need to Improve Consent and Privacy Standards</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690694</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;In March, the publication of the complete genome sequence of cancer cells from a Maryland woman who died in 1951 ignited an ethical firestorm. These cells, called HeLa because they were derived from the cervical tumor of Henrietta Lacks, have been widely cultured in laboratories and used in research.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2083</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2084</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5048</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690694</guid>
    </item>
    <item>
      <title>Physicians, Patients Not Following Advice From USPSTF on Mammography Screening</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690695</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Mitka M. </author>
      <description>&lt;span class="paragraphSection"&gt;In 2009, the US Preventive Services Task Force (USPSTF) recommended against routine screening mammography for women aged 40 to 49 years and advised biennial rather than annual screening for women aged 50 to 74 years. But it appears that women and physicians have ignored these recommendations.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2084</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2084</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5951</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690695</guid>
    </item>
    <item>
      <title>Residencies Roll Out New Training System</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690696</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Mitka M. </author>
      <description>&lt;span class="paragraphSection"&gt;Medical residency programs are about to undergo substantial changes in the ways the physicians of tomorrow are trained.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2085</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2086</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.3943</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690696</guid>
    </item>
    <item>
      <title>From  JAMA  ’s Daily News Site</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690698</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description />
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2086</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2086</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.6020</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690698</guid>
    </item>
    <item>
      <title>Exercise and Teen Smoking</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690683</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;Increasing physical activity may help teens reduce or quit smoking, according to a study funded by the US Centers for Disease Control and Prevention.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2087</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2087</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5931</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690683</guid>
    </item>
    <item>
      <title>Major Brain Research Program</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690681</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;A new federally funded “big science” project will probe the inner workings of the brain. The initiative, announced by President Obama in April, will be funded by the Defense Advanced Research Projects Agency, the National Institutes of Health, and the National Science Foundation.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2087</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2087</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5626</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690681</guid>
    </item>
    <item>
      <title>Neonatal Trial Criticized for Inadequate Consent </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690682</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;The US Office for Human Research Protections (OHRP) has determined that a large multisite clinical trial comparing the effects of differing levels of oxygen supplementation for neonates failed to obtain proper consent from the parents of enrolled infants.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2087</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2087</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5928</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690682</guid>
    </item>
    <item>
      <title>Safer Oxycodone</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690680</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Kuehn BM. </author>
      <description>&lt;span class="paragraphSection"&gt;Only an abuse-resistant name-brand formulation of oxycodone will be allowed to remain on the market, according to the US Food and Drug Administration (FDA). In April 2013, the agency withdrew approval of the original form of the drug and noted that it will not accept generic drug applications from companies seeking to reproduce the original formulation.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2087</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2087</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5921</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690680</guid>
    </item>
    <item>
      <title>American Picnic</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690676</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Cole TB. </author>
      <description>&lt;span class="paragraphSection"&gt;Judging from their body language, the casually dressed women and men in Roland Petersen's American Picnic (cover) aren't having a pleasant afternoon. With the exception of two couples in conversation to pass the time, the picnickers don't seem to know one another or be making an effort to get acquainted. The ambience is obligatory, like a corporate function; if this scene had been painted from life, it would hardly seem worth commemorating. The painting is probably not based on a real event, but is rather a composite of views from the Sacramento Valley of California assembled by the painter to create a sense of rhythm and spatial recession. In this painting, the human figures are intentionally deanimated. Petersen said that he admired the rigidity and silence of Egyptian art and the stiff postures of the bourgeoisie in the pointillist paintings of Georges Seurat. Picnic scenes were particularly well suited to Petersen's artistic goal, which was to create a plausible composition of human figures and landscape features in a large, open-air still life. The figures and objects function as pictorial elements that mark intervals of color and geometric shapes. &lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2078</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2078</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.1598</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690676</guid>
    </item>
    <item>
      <title>Infinitive</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690701</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author> McMahon T. </author>
      <description>&lt;span class="paragraphSection"&gt;To walk is to fallwith every step, yettrust in the next.To love is to open, willingto give everything away.To comfort is to sharewhat cannot be changed.To grieve is to graspthe fullness of letting go.To live is to be presentin this step, this breath.To die? Finally to know.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2079</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2079</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2012.233595</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690701</guid>
    </item>
    <item>
      <title>THE OFFICE OF CORONER</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690684</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;May 24, 1913&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2080</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2080</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2012.174849</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690684</guid>
    </item>
    <item>
      <title>CDC Offers Primer on Blast Injury Care</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690709</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;In the aftermath of bombings at the Boston marathon on April 15, the Centers for Disease Control and Prevention (CDC) has alerted health professionals that its website on mass casualty event preparedness and response contains extensive information for them, their patients, and the general public. &lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2088</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2088</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5628</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690709</guid>
    </item>
    <item>
      <title>Nematode Infection Is Transmitted via Organ Transplants</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690712</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;Infection with an intestinal nematode transmitted via organ transplants may be more common than previously believed.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2089</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2089</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5627</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690712</guid>
    </item>
    <item>
      <title>Ohio Varicella Death Is Vaccination Wake-up Call</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690710</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;The death of an Ohio teen from varicella should serve as a reminder that catch-up vaccination of older children and adolescents can prevent severe complications and death from infection with varicella-zoster virus.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2088</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2088</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5622</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690710</guid>
    </item>
    <item>
      <title>US Infant Mortality Decreases but Still Ranks High Worldwide</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690711</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;After significant decreases throughout the 20th century, the US infant mortality rate plateaued from 2000 to 2005 and now is declining again. However, the US infant mortality rate still ranks 27th among the 34 countries of the Organization for Economic Cooperation and Development.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2089</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2089</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.5621</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690711</guid>
    </item>
    <item>
      <title>Conjunctivitis</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690700</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author>Goodman DM, Rogers J, Livingston EH. </author>
      <description>&lt;span class="paragraphSection"&gt;The conjunctiva is a thin membrane covering the inside of the eyelids and the white part of the eye (the sclera). Inflammation or infection of the conjunctiva is called conjunctivitis (“pink eye”). It can be caused by viruses, bacteria, or fungi; allergy; exposure to chemicals or irritants; or long-term presence of a foreign body, such as hard or rigid contact lenses.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2176</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2176</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4432</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690700</guid>
    </item>
    <item>
      <title>About This Journal</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1690703</link>
      <pubDate>Wed, 22 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description />
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">20</prism:number>
      <prism:startingPage xmlns:prism="prism">2067</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2067</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.309.20.2067</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1690703</guid>
    </item>
  </channel>
</rss>